Allogeneic Immune Cell Solutions

Mycenax has pre-built state-of-the-art manufacturing platforms specialized for allogeneic immune cell therapies, supporting every step from research, pre-clinical and clinical development to commercialization. We understand the complexity of scalable manufacturing allogeneic immune cell products, and we have developed solutions to resolve the bottleneck of scale-up and achieve cost-effective manufacturing for our partners. Whether for genetically modified or non-genetically modified cells, our flexible and efficient technology platform is dedicated to meet diverse needs, offering end-to-end and flexible support from innovation to clinical implementation.

"We provide a one-stop, stable, efficient, and scalable cell manufacturing solution.

Our standardized process ensures high-yield and high-quality cell expansion."

Expert on Allogeneic Immune Cell Therapies

We are specialized in allogeneic immune cell therapies including but not limit to γδT and NK. Whether your needs are gene or non-gene modified, allogeneic, our CGT team provide a wide range supports to meet your diverse demands on immune cell products.    

Immune cells

Cell Type

γδT

PBNK

Process

250 mL
peripheral blood

One

leukopak

One cord

blood unit

γδTMX™

NKMX™

Production

time

3 weeks

3 weeks

3 weeks

Production cell numbers

>4x10¹⁰

>2x10¹³

>1x10¹³

Production doses

280 doses

>20,000 doses

>10,000 doses

Gene engineered

Feeder cell line development

Cell Type

CAR-

γδT

CAR-PBNK

CAR-CBNK

Gene-engineered K562

Process

3rd-generation lentiviral vector

Transposon

Production

time

3 weeks

3 weeks

3 weeks

7 months

Production cell numbers

>4x10¹⁰

>2x10¹³

>1x10¹³

Production doses

280 doses

>20,000 doses

>10,000 doses

-

Customized Cell Culture Equipment Options for Every Development Phase

A full range of configurable cell culture systems—spanning scale-down models to clinical-scale bioreactors—allows tailored equipment selection to meet phase-specific production requirements.

Culture type

Scale

Static culture

G-Rex

Multiple well

(Scale-down model)

50M

100M

500M

Vessel

Stage

Research and drug discovery

Research and drug discovery, Preclinical

Preclinical, 

Clinical Phase I

Culture type

Dynamic

(Suspension) culture

Stir tank bioreactor

Ambr250®

(Scale-down model)

2L

Vessel

Stage

Research and drug discovery, Preclinical

Culture type

Dynamic

(Suspension) culture

Stir tank bioreactor

10L

50L

Vessel

Stage

Clinical Phase II

Clinical Phase III

NKMX™ Platform

Our proprietary NKMX™ platform, a feeder-dependent process technology, offers unique advantages in allogeneic NK manufacturing — eliminating donor variation, achieving high cell yield and purity, and enabling scalable production up to 50 L bioreactors. The platform ensures batch-to-batch consistency, superior quality, and cost-effectiveness, empowering CGT developers to rapidly translate allogeneic off-the-shelf NK products from development to clinical application.

NKMX™ Platform Key Features: 

◆

2 Cell Source

◆

3W+ Turnaround Time

◆

1-50L Flexible Scale

◆

>10⁵ Doses

◆

>95% Cell purity

◆

>12M Long-Term Storage Stability

γδTMX™ Platform

The γδTMX™ platform, an advanced and scalable γδT-cell process technology, is designed to efficiently expand and manufacture high-purity allogeneic Vγ9Vδ2 T cells for therapeutic applications. By leveraging N-BP drugs for γδT-cell activation, the platform enhances cell expansion and functional potency while ensuring therapeutic efficacy. It enables large-scale, GMP-compliant production with maintained cellular integrity.
Key advantages include high expansion capacity, exceptional purity, and the consistent generation of a dominant memory T-cell subpopulation that supports long-term efficacy and persistence. The γδTMX™ platform empowers CGT developers to rapidly translate allogeneic, off-the-shelf γδT-cell products from development to clinical application.

γδTMX™ Platform Key Features:

◆

>90% Cell Purity

◆

<1% αβT cell impurity

◆

>10² Doses